DARAXONRASIB (RMC-6236), GEMCITABINE HYDROCHLORIDE, PACLITAXEL ALBUMIN-BOUND, GEMCITABINE HYDROCHLORIDE, OXALIPLATIN, GEMCITABINE HYDROCHLORIDE, DARAXONRASIB (RMC-6236), GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE, IRINOTECAN, IRINOTECAN HYDROCHLORIDE, FOLINIC ACID, FLUOROURACIL, GEMCITABINE HYDROCHLORIDE
RMC-6236-302
Phase 3 small_molecule active
Quick answer
DARAXONRASIB (RMC-6236), GEMCITABINE HYDROCHLORIDE, PACLITAXEL ALBUMIN-BOUND, GEMCITABINE HYDROCHLORIDE, OXALIPLATIN, GEMCITABINE HYDROCHLORIDE, DARAXONRASIB (RMC-6236), GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE, IRINOTECAN, IRINOTECAN HYDROCHLORIDE, FOLINIC ACID, FLUOROURACIL, GEMCITABINE HYDROCHLORIDE for Metastatic Pancreatic Ductal Adenocarcinoma is a Phase 3 program (small_molecule) at Revolution Medicines with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Revolution Medicines
- Indication
- Metastatic Pancreatic Ductal Adenocarcinoma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active